Hologic's (Nasdaq:HOLX)
difficult midlife crisis continues. With its core cervical cancer
screening business struggling in response to new recommended testing
intervals and the 3D tomo mammography business slow to ramp up, Hologic
is a distressing mix of sluggish organic growth
and a debt-laden balance sheet. While some investors seemed encouraged
by the company's move to bring back its former CEO, there's a lot of
work to be done to carve out an attractive growth path for this company.
Please read the full article here:
http://www.investopedia.com/stock-analysis/080713/hologic-struggling-find-new-path-holx-dgx-ge-bdx.aspx
No comments:
Post a Comment